Pharmacological and behavioral characterization of the novel CRF 1 antagonist BMS-763534

Neuropharmacology

Volumn 67, Issue , 2013, Pages 284-293

  Lodge, Nicholas J ^a,b   Lelas, Snjezana ^a   Li, Yu Wen ^a   Molski, Thaddeus ^a   Grace, James ^a   Sivarao, Digavalli V ^a   Post Munson, Debra ^a   Healy, Francine ^a   Bronson, Joanne J ^a   Hartz, Richard ^a   MacOr, John E ^a   Zaczek, Robert ^a,b  

^a BRISTOL MYERS SQUIBB   (United States)

^b NeurOp Inc   (United States)

Author keywords

Anxiolytic; Corticotropin releasing factor (CRF); CRF type 1 receptor antagonist; GABAA; Subjective effects

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; ANXIOLYTIC AGENT; BMS 763534; BMS 790318; CHLORDIAZEPOXIDE; CORTICOSTERONE; CORTICOTROPIN RELEASING FACTOR; CORTICOTROPIN RELEASING FACTOR ANTAGONIST; CORTICOTROPIN RELEASING FACTOR RECEPTOR 1; DIAZEPAM; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANXIETY DISORDER; ARTICLE; BINDING AFFINITY; BINDING SITE; CONTROLLED STUDY; CORTICOSTERONE BLOOD LEVEL; DISSOCIATION; DOSE RESPONSE; DRUG BINDING SITE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG RECEPTOR BINDING; DRUG STRUCTURE; HUMAN; HUMAN CELL; IC 50; IMMOBILIZATION STRESS; LOCOMOTION; MALE; MOTOR COORDINATION; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR OCCUPANCY;

AMINOPYRIDINES; ANIMALS; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MALE; MOTOR ACTIVITY; PROTEIN BINDING; PYRAZINES; RATS; RATS, INBRED SHR; RECEPTORS, CORTICOTROPIN-RELEASING HORMONE; SHEEP; SWINE;

EID: 84873348038     PISSN: 00283908     EISSN: 18737064     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2012.10.025     Document Type: Article

References (43)

1. R. Adamec, D. Fougere, and V. Risbrough CRF receptor blockade prevents initiation and consolidation of stress effects on affect in the predator stress model of PTSD Int. J. Neuropsychopharm. 13 2010 747 757
2. R. Alonzo, G. Griebel, G. Pavone, J. Stemmelin, G. Le Fur, and P. Soubrie Blockage of CRF1 or V1b receptors reverses stress-induced suppression of neurogenesis in a mouse model of depression Mol. Psych. 9 2004 278 286
3. D.R. Britton, G.F. Koob, J. Rivier, and W. Vale Intraventricular corticotropin-releasing factor enhances behavioral effects of novelty Life Sci. 31 1982 363 367
4. L. Carpenter, A. Tyrka, C.J. McDougle, R.T. Malison, M.J. Owens, B. Nemeroff, and L.H. Price Cerebral spinal fluid corticotropin-releasing factor and perceived early-life stress in depressed patients and healthy control subjects Neuropsychopharmacology 29 2004 777 784
5. D.T. Chalmers, T.W. Lovenberg, and E.B. De Souza Localization of novel corticotropin-releasing factor receptor (CRF2) mRNA expression to specific subcortical nuclei in rat brain: comparison with CRF1 receptor mRNA expression J. Neurosci. 15 1995 6340 6350
6. L.A. Fisher Central actions of corticotropin-releasing factor on autonomic nervoue activity and cardiovascular functioning Corticotropin- releasing Factor 1993 Wiley 243 257
7. D.R. Gehlert, A. Cippitelli, A. Thorsell, A.D. Le, P.A. Hipskind, C. Hamdouchi, J. Lu, E.J. Hembre, J. Cramer, M. Song, D. McKinzie, M. Morin, R. Ciccocioppo, and M. Heilig 3-(4-chloro-2-morpholin-4-yl-thiazol-5-yl)-8-(1- ethylpropyl)-2,6-dimethyl-imidazo[1,2-b]pyridazine: a novel brain-penetrant, orally available corticotropin-releasing factor receptor 1 antagonist with efficacy in animal models of alcoholism J. Neurosci. 27 2007 2718 2726
8. R.L. Hauger, J.A. Olivares-Reyes, S. Braun, K.J. Catt, and F.M. Dautzenberg Mediation of corticotropin releasing factor type 1 receptor phosphorylation and desensitization by protein kinase C: a possible role in stress adaptation J. Pharmacol. Exp. Ther. 306 2003 794 803
9. M. Heilig, and G.F. Koob A key role for corticotropin-releasing factor in alcohol dependence Trends Neurosci. 30 2007 399 406
10. L.J. Herberg, and S.F. Williams Anti-conflict and depressant effects of GABA agonists and antagonists, benzodiazepines and non-GABAergic anticonvulsants on self-stimulation and locomotor activity Pharmacol. Biochem. Behav. 19 1983 625 633
11. N. Hiroi, M.L. Wong, J. Licinio, C. Park, M. Young, P.W. Gold, G. Chrousos, and S.R. Bornstein Expression of corticotropin releasing hormone receptors type I and type II mRNA in suicide victims and controls Mol. Psych. 6 2001 540 546
12. S.R.J. Hoare, S.K. Sullivan, N. Ling, P.D. Crowe, and D.E. Grigoriadis Mechanism of corticotropin-releasing factor type 1 receptor regulation by nonpeptide antagonists Mol. Pharmacol. 63 2003 751 765
13. Institute of the Laboratory Animal Resources, Commission on Life Sciences, National Research Council Guide for the Care and Use of Laboratory Animals seventh ed. 1996 National Academy Press Washington, DC
14. J.H. Kehne, and C.K. Cain Therapeutic utility of non-peptidic CRF1 receptor antagonists in anxiety, depression, and stress-related disorders: evidence from animal models Pharmacol. Ther. 128 2010 460 487
15. G.F. Koob The role of CRF and CRF-related peptides in the dark side of addiction Brain Res. 1314 2010 3 14
16. A) receptor J. Pharmacol. Exp. Ther. 277 1996 1784 1792
17. R. Lee, T.D. Geracioti, J.W. Kasckow, and E.F. Coccaro Childhood trauma and personality disorder: positive correlation with adult CSF corticotropin-releasing factor concentrations Am. J. Psychiatry 16 2005 995 997
18. S. Lelas, K.L. Zeller, K.A. Ward, and J.F. McElroy The anxiolytic CRF1 antagonist DMP696 fails to function as a discriminative stimulus and does not substitute for chlordiazepoxide in rats Psychopharmacology 166 2003 408 415
19. S. Lelas, H. Wong, Y.-W. Li, K.L. Heman, K.A. Ward, K.L. Zeller, K.K. Sieracki, J.L. Polino, H.E. Godonis, S.X. Ren, X.-X. Yan, S.P. Arneric, D.W. Robertson, P.R. Hartig, S. Grossman, G.L. Trainor, R.,A. Taub, R. Zaczek, P.J. Gilligan, and J.F. McElroy Anxiolytic-like effects of the CRF1 antagonist DMP904 administered acutely or chronically at doses occupying central CRF1 receptors in rats J. Pharmacol. Exp. Ther. 309 2004 293 302
20. 1 antagonist DMP696: correlation with drug exposure and anxiolytic efficacy J. Pharmacol. Exp. Ther. 305 2003 86 96
21. 1 antagonists CNS Drug Rev. 11 2005 21 52
22. C. Maillot, M. Million, J.Y. Wei, A. Gauthier, and Y. Tache Peripheral corticotropin-releasing factor and stress-stimulated colonic motor activity involve type 1 receptor in rats Gastroenterology 119 2000 1569 1579
23. V. Martinez, J. Rivier, L. Wang, and Y. Tache Central injection of a new corticotropin-releasing factor (CRF) antagonist, astressin, blocks CRF- and stress-related alterations of gastric and colonic motor function J. Pharmacol. Exp. Ther. 280 1997 754 760
24. M. Million, D.E. Grigoriadis, S. Sullivan, P.D. Crowe, J.A. McRoberts, H. Zhou, P.R. Saunders, C. Maillot, E.A. Mayer, and Y. Tache A novel water-soluble selective CRF1 receptor antagonist, NBI 35965, blunts stress-induced visceral hyperalgesia and colonic motor function in rats Brain Res. 985 2003 32 42
25. M.B. Müller, S. Zimmermann, I. Sillaber, T.P. Hagemeyer, J.M. Deussing, P. Timpl, M.S.D. Kormann, S.K. Droste, R. Kühn, J.M.H.M. Reul, F. Holsboer, and W. Wurst Limbic corticotropin-releasing hormone receptor 1 mediates anxiety-related behavior and hormonal adaptation to stress Nat. Neurosci. 6 2003 1100 1107
26. C.B. Nemeroff, and W.W. Vale The neurobiology of depression: in-roads in treatment and new drug discovery J. Clin. Psych 66 2005 5 13
27. D.H. Overstreet, and G. Griebel Antidepressant-like effects of CRF1 receptor antagonist SSR125543 in an animal model of depression Eur. J. Pharmacol. 497 2004 49 53
28. R.J. Primus, E. Yevich, C. Baltazar, and D.W. Gallager Autoradiographic localization of CRF1 and CRF2 binding sites in adult rat brain Neuropsychopharmacology 17 1997 308 316
29. A.T. Ramos, L.R. Troncone, and S. Tufik Suppression of adrenocorticotrophic hormone secretion by simultaneous antagonism of vasopressin 1b and CRH-1 receptors on three different stress models Neuroendocrinology 951 2006 1 8
30. C.R. Schuster, M.W. Fischman, and C.E. Johanson Internal stimulus control and subjective effects of drugs NIDA Res. Monogr. 37 1981 116 129
31. R.D. Sofia Comparison of two methods for measuring drug-induced neurotoxicity J. Pharm. Sci. 58 1969 900 901
32. T. Steckler, and F.M. Dautzenburg Corticotropin-releasing factor receptor antagonists in affective disorders and drug-dependence-an update CNS Neurol. Disord.-Drug Targets 5 2006 147 165
33. A. Steiger Sleep and endocrinology J. Intern. Med. 254 2003 13 22
34. A. Stengel, and Y. Tache Corticotropin-releasing factor signaling and visceral response to stress Exp. Biol. Med. 235 2010 1168 1178
35. A. Strohle, and F. Holsboer Stress responsive neurohormones in depression and anxiety Pharmacopsychology 36 2003 S207 214
36. E.M. Strome, G.H.T. Wheeler, J.D. Higley, D.L. Loriaux, S.J. Suomi, and D.J. Doudet Intracerebroventricular corticotropin-releasing factor increases limbic glucose metabolism and has social context-dependent behavioral effects in nonhuman primates PNAS 99 2002 15749 15754
37. N. Suman-Chauhan, P. Carnell, R. Franks, L. Webdale, N.S. Gee, S. McNulty, C.J. Rossant, D. Van Leeuwen, R. MacKenzie, and M.D. Hall Expression and characterisation of human and rat CRF2alpha receptors Eur. J. Pharmacol. 379 1999 219 227
38. S. Sweetser, M. Camilleri, S.J. Linker Nord, D.D. Burton, L. Castenada, R. Croop, G. Tong, R. Dockens, and A.R. Zinsmeister Do corticotropin releasing factor-1 receptors influence colonic transit and bowel function in women with irritable bowel syndrome? Am. J. Physiol. Gastrointest. Liver Physiol. 296 2009 G1299 1306
39. Y. Tache, and M.H. Perdue Role of peripheral CRF signaling pathways in stress-related alterations of gut motility and mucosal function Neurogastroenterol. Motil. 16 2004 137 142
40. P. Timpl, R. Spanagel, I. Sillaber, A. Kresse, J.M.H.M. Reul, G.K. Stalla, V. Blanqurt, T. Steckler, F. Holsboer, and W. Wurst Impaired stress response and reduced anxiety in mice lacking a functional corticotropin- releasing hormone receptor 1 Nat. Genet. 19 1998 162 166
41. 1 receptors J. Pharmacol. Exp. Ther. 305 2003 57 69
42. E.P. Zorrilla, and G.F. Koob Progress in corticotropin-releasing factor-1 antagonist development Drug Discov. Today 15 2010 371 383
43. E.P. Zorrilla, Y. Tache, and G.F. Koob Nibbling at CRF receptor control of feeding and gastrocolonic motility TIPS 24 2003 421 427